VIVA Biotech AGM: Shareholders Pass All Resolutions with Over 97% Support

VIVA Biotech (01873) reported that every agenda item tabled at its 26 June 2026 Annual General Meeting in Shanghai received the required simple majority, underscoring broad shareholder backing for the company’s strategic and governance proposals.

Key outcomes

1. Financial statements and auditor’s report: The FY 2025 audited consolidated financial statements and accompanying reports were adopted with 99.93% of votes cast in favour (887.08 million shares), versus 0.07% (0.63 million shares) against.

2. Board composition: • Executive Director Ren Delin, Non-executive Director Wu Yuting and Independent Non-executive Director Fu Lei were each re-elected with 99.99% approval (987.69 million shares for; 0.01% or 0.01 million shares against for each candidate).

3. Directors’ remuneration: The Board was authorised to set directors’ pay, backed by 99.99% of votes (887.69 million for; 0.01 million against).

4. Auditor appointment: Ernst & Young was re-appointed, also securing 99.99% shareholder endorsement (887.69 million for; 0.01 million against).

5. Capital authorities: • General issuance mandate: Directors may allot or transfer shares up to 20% of issued capital, supported by 97.69% of votes (867.23 million for; 20.48 million against). • Share repurchase mandate: Approval to repurchase up to 10% of issued capital passed with 99.99% support (887.69 million for; 0.01 million against). • Mandate extension: The issuance mandate can be extended by the number of shares repurchased, receiving 97.69% approval (867.23 million for; 20.48 million against).

Voting base and attendance

• Total issued shares: 2.10 billion, including 9.49 million repurchased shares pending cancellation (non-voting). • Voting shares eligible: 2.10 billion. • No shares carried voting restrictions or required abstention, and no shareholder expressed an intention to oppose any resolution. • Tricor Investor Services acted as scrutineer. All directors participated either in person or electronically.

The strong voting margins provide the Board with renewed flexibility on capital management and affirm shareholder confidence in the company’s governance and strategic direction.